Methisoprinol (Inosine Pranobex) for Mumps During a Local Outbreak: Findings from a Descriptive Single-Center Study

Rochman Mujayanto*    -  (Scopus ID : 57221256524) Departement of Oral Medicine, Universitas Islam Sultan Agung, Indonesia

(*) Corresponding Author
DOI: 10.30659/medali.7.2.103-108

Background: Mumps is an acute infectious disease caused by the paramyxovirus, commonly found in many countries. In 2024, mumps outbreaks were reported globally, with significant cases in India (18,158), the USA (328), the Netherlands (578), and Indonesia (413). The current treatment guidelines for mumps are paracetamol or ibuprofen for pain relief. Purpose: To describe clinical profiles and outcomes of mumps patients treated with methisoprinol in a single-center cross-sectional study. Methods: A descriptive cross-sectional study of mumps patients treated with methisoprinol was conducted at the Islamic Dental Hospital Sultan Agung, Semarang, using retrospective data from August to December 2024. Mumps was defined by the WHO's clinical definition of parotid gland swelling. Results: Among 35 mumps patients, there was an almost equal gender distribution, with most being under 18. The majority had a history of febrile illness, used symptomatic medication, and lacked MMR vaccination history. There was a significant difference in the duration of parotitis before and after methisoprinol medication. Factors like sex, age, parotitis location, and MMR vaccination history did not significantly affect recovery time. Conclusion: Methisoprinol significantly reduced the duration of parotitis, while sex, age, parotitis location, and MMR vaccination history did not significantly influence recovery time.

Keywords: Paramyxovirus; Mumps; Methisiprinol; Inosine Pranobex

  1. CDC. Mumps Cases and Outbreaks [Internet]. Centers for Disease Control and Prevention. 2024 [cited 2024 Dec 23]. Available from: https://www.cdc.gov/mumps/outbreaks/index.html#cdc_data_surveillance_section_2-reported-u-s-mumps-cases-by-jurisdiction-2024
  2. WHO South-East Asia Region. Epidemiological Bulletin 7th Edition. World Health Organization. 2024 Apr;1–13.
  3. RIVM. Current figures on mumps in the Netherlands [Internet]. Dutch National Institute for Public Health and the Environment. 2024 [cited 2024 Dec 23]. Available from: https://www.rivm.nl/en/mumps/current-figures
  4. Ministry of Health Republic Indonesia. Alertness to the rise of mumps cases. Jakarta; 2024.
  5. WHO. Mumps [Internet]. World Health Organization. 2024 [cited 2024 Dec 23]. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/mumps
  6. Boyle C, Asimakopoulos P, Khatamzas E, Vernham G. Mumps presenting with unilateral, synchronous parotid and submandibular gland swelling. BMJ Case Rep. 2018;2018:1–4.
  7. Grennan D. Outbreaks ofmumps in the United States have increased since 2006. JAMA. 2019;322(10):2019.
  8. Srinivasan S, Torres AG, Ribas de Pouplana L. Inosine in Biology and Disease. Genes (Basel) [Internet]. 2021 Apr 19;12(4):600. Available from: https://pubmed.ncbi.nlm.nih.gov/33921764
  9. Beran J, Špajdel M, Katzerová V, Holoušová A, Malyš J, Finger Rousková J, et al. Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic. Pathogens. 2020;9(12).
  10. Sliva J, Pantzartzi CN, Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther [Internet]. 2019;36(8):1878–905. Available from: https://doi.org/10.1007/s12325-019-00995-6
  11. Beran J, Šalapová E, Špajdel M, Team on behalf of the IS (EWO I 2014/1). Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis [Internet]. 2016;16(1):648. Available from: https://doi.org/10.1186/s12879-016-1965-5
  12. Kaczmarczyk D, Zagacki D, Morawiec-Sztandera A. Upper respiratory tract infection in children – immunostimulating treatment. J Educ Heal Sport [Internet]. 2021 Sep 6;11(9 SE-Review Articles):80–9. Available from: https://apcz.umk.pl/JEHS/article/view/JEHS.2021.11.09.011
  13. Lasek W, Janyst M, Wolny R, Zapała Ł, Bocian K, Drela N. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm [Internet]. 2015;65(2):171–80. Available from: https://doi.org/10.1515/acph-2015-0015
  14. Janíčková O, Ancičová L, Briestenská K, Mistríková J. The effect of isoprinosine treatment on persistent infection of Balb/c mice infected with murine gammaherpesvirus 68. Acta Virol. 2017;61(1):32–8.
  15. Kim IS, Jo EK. Inosine: A bioactive metabolite with multimodal actions in human diseases. Front Pharmacol [Internet]. 2022;13. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1043970
  16. Kushner LE, Kamens J, Bertaina A, Shyr D, Gans HA. Vaccine Associated Measles Complicated by Suspected Measles Inclusion Body Encephalitis in a Pediatric Leukemia Patient and Stem Cell Transplant Recipient: A Focus on Clinical Evolution and Management. Pediatr Infect Dis J [Internet]. 2024;43(6). Available from: https://journals.lww.com/pidj/fulltext/2024/06000/vaccine_associated_measles_complicated_by.20.aspx
  17. Tuncel D, Ozbek AE, Demirpolat G, Karabiber H. Subacute Sclerosing Panencephalitis with Generalized Seizure as a First Symptom: A Case Report. Jpn J Infect Dis. 2006;59(5):317–9.

Lisensi Creative Commons
This work is licensed under a Lisensi Creative Commons Atribusi-BerbagiSerupa 4.0 Internasional.
Contact us: MEDALI Jurnal: Media Dental Intelektual : Jl. Raya Kaligawe Km.4, PO BOX 1054/SM Semarang, Central Java, Indonesia, 50112. Email: odontodentaljournal@unissula.ac.id
apps